Clinical trial readout dates for Mirum Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
| Phase 2 Volixibat Primary Biliary Cholangitis; PBC · NCT05050136 | January 2027 Ongoing |
| Phase 3 Brelovitug 300 mg Chronic Hepatitis D Infection · NCT07200908 | June 2027 Recruiting |
| Phase 2/3 Brelovitug (BJT-778) Chronic Hepatitis D · NCT07454837 | August 2027 Recruiting |
| Phase 2 Low dose of MRM-3379 Fragile X Syndrome · NCT07209462 | October 2027 Recruiting |
| Phase 2 Maralixibat Intrahepatic Cholestasis of Pregnancy · NCT07823127 | January 2029 Not Yet Recruiting |
| Phase 2/3 Brelovitug 300 mg Chronic Hepatitis D Infection · NCT06907290 | May 2029 Ongoing |
Mirum Pharmaceuticals Inc. reported $670M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $41M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Other Events — often topline trial data | 2026-11-10 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |
| 8-K Other Events — often topline trial data | 2026-10-26 |